Biopharma companies appear to be more willing to go public after a long drought. Just this week, GLP-1 developer Kailera Therapeutics and proteomics company Alamar Biosciences launched IPO roadshows ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

Large language models trained on vast datasets could speed genomics research, streamline clinical documentation, improve real-time diagnostics, support clinical decision-making, accelerate drug ...

Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...

Novo Nordisk A/S will partner with US biotech firm Vivtex Corp. to develop next-generation drugs for obesity, diabetes and other metabolic diseases in a deal potentially worth up to $2.1 billion. The ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Research Scientist in Lab For years, public debate around U.S. dependence on China has ...

China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in the country. Experts say this could slow down American innovation in the biotech space. China's ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

A run of pharmaceutical mergers and acquisitions is fueling optimism that biotechnology venture capital is poised to rebound from its postpandemic slump. With $223 billion in biotech M&A deals ...

Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...

Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls "the patent cliff." The need for pharma to top up their ...